Clinical Trial Search

Primary: Tenderness (Algometry) Over the Initial 72 Hours — 1213.88; 1041.04; 850.79 Nxh/cm^2 — p=0.0221

Primary: Measure Changes Clinically in Crestal Soft Tissue Thickness (in mm) — 1.96; 1.59; 0.33 mm

Primary: Change in Buccal Plate Thickness From Baseline to Month 6 — 1.85; 1.25 mm — p=0.11

Primary: Objective Response Rate — 1; 7; 11 participants

Primary: Landing Error Scoring System (LESS) Score — 6; 5.8; 5.2 errors

Primary: Change in Post Traumatic Concerns Over the Course of the Six Months After Injury — 80; 83; 55; 59 Participants — p==0.01

Primary: 4 Hour Mortality — 50; 32 Participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Mid Facial Mucosal Level at Implant Site — 0.36; 0.49 mm

Primary: Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR) — 9.4; 9.4; 0.0; 16.1 Percentage of participants

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants

Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43

Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants

Primary: The FMS™ Score — 13.5 FMS Score